These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 31256417)

  • 21. Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study.
    Yang JM; Jung SY; Kim MS; Lee SW; Yon DK; Shin JI; Lee JY
    Ophthalmology; 2024 Jul; ():. PubMed ID: 39004231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-induced tumoral disease: A global pharmacovigilance database analysis.
    Zelmat Y; Despas F
    Therapie; 2024; 79(2):189-197. PubMed ID: 38042752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System.
    Sorbara EE; Barbieri MA; Russo G; Cicala G; Spina E
    BioDrugs; 2024 Mar; 38(2):275-285. PubMed ID: 38402495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics.
    Minjon L; van den Ban E; de Jong E; Souverein PC; Egberts TCG; Heerdink ER
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):124-132. PubMed ID: 30676073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Bhushan S; Ray RS; Prakash J; Singh GN
    Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
    Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
    Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
    Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
    Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
    Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
    Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.
    Scavone C; Di Mauro C; Ruggiero R; Bernardi FF; Trama U; Aiezza ML; Rafaniello C; Capuano A
    Drugs Real World Outcomes; 2020 Mar; 7(1):41-51. PubMed ID: 31848905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
    Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
    J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety profile of etifoxine: A French pharmacovigilance survey.
    Cottin J; Gouraud A; Jean-Pastor MJ; Dautriche AD; Boulay C; Geniaux H; Auffret M; Bernard N; Descotes J; Vial T
    Fundam Clin Pharmacol; 2016 Apr; 30(2):147-52. PubMed ID: 26588183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
    Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.
    Kalaiselvan V; Sharma S; Singh GN
    Drug Saf; 2014 Sep; 37(9):703-10. PubMed ID: 25085041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
    Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
    Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
    Star K; Norén GN; Nordin K; Edwards IR
    Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016.
    Ha D; Choi SR; Kwon Y; Park HH; Shin JY
    Medicine (Baltimore); 2019 Aug; 98(33):e16785. PubMed ID: 31415382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010-2019.
    Montastruc JL
    Br J Clin Pharmacol; 2023 Jan; 89(1):201-208. PubMed ID: 35881623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database.
    Ruggiero R; Fraenza F; Scavone C; di Mauro G; Piscitelli R; Mascolo A; Ferrajolo C; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Pharmacol; 2020; 11():830. PubMed ID: 32581796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.